Author Archives: admin


Share the Love on Valentine’s Day! Join the Cure 4 The Kids Foundation Blood Drive and Registry Event – Nevada Business Magazine

LAS VEGAS Regardless of your relationship status on Valentines Day, you can have an incredible impact on someones life in our communityand possibly save a life by donating blood or by becoming part of the bone marrow registry.

Cure 4 The Kids Foundation is well aware of the national shortage of blood and platelets, and how vital a reliable blood supply is to the on-going health of our community. Thats why Cure 4 The Kids Foundation is organizing the Valentines Day Blood Drive and Bone Marrow Registry Event on Friday, February 14, 2020.

The public is strongly encouraged to take part in either effort between 9:00 a.m. and 4:00 p.m. at One Breakthrough Way, Las Vegas, Nevada 89135.

Blood donors can ensure an easy and relatively quick donation process by making an appointment prior to Valentines Day by going towww.bloodhero.comand entering the code: cure4kids under sponsor. You can also schedule an appointment by calling Vitalant at 877-25-VITAL. The Vitalant bloodmobile will be parked in front of the One Breakthrough Way building.

Blood Donation Reminders:

Blood donors must be at least 16 years old (16 and 17-year olds must bring a signed permission form from a parent or guardian)Weigh at least 110 poundsBe in good general healthDrink plenty of water 24 to 48 hours prior to donationBring ID

Cure 4 The Kids Foundation is also partnering with the Be The Match Registry. The registry offers hope to those affected by cancer and other conditions by matching potential blood stem cell donors with those who are in need of a transplant.

The first step in joining the registry is to undergo a mouth swab by one of our volunteers. Those who are a possible match will be contacted at a later time. This service is free and available between 9:00 a.m. and 4:00 p.m. on February 14, 2020, in the lobby of the One Breakthrough Way building.

Bone Marrow Registry Reminders:

Donors between 18 and 44 years of age are especially neededYou cannot become a donor if you had have certain diseasesLearn more atjoin.bethematch.org

About Cure 4 The Kids Foundation

Founded in Las Vegas in 2007, Cure 4 The Kids Foundation exists to provide high-quality, research-focused medical treatment to children battling cancer and many other life-threatening conditions. Cure 4 The Kids Foundation operates the only outpatient childhood cancer treatment center in the State of Nevada and is proudly accredited by The Joint Commission. This stringent medical accreditation and the required unannounced inspections ensure that patients are getting the best care possible. From the beginning, the mission of Cure 4 The Kids Foundation has been to bring increased community access to these specialized treatments that are leading the way to improved patient outcomes. Cure 4 The Kids Foundations Charity Care Program provides high-quality treatment to those who are uninsured, underinsured and those unable to pay for treatment. No patient is ever turned away for financial reasons. We are a 501(c)(3) nonprofit organization.www.cure4thekids.org

Continued here:
Share the Love on Valentine's Day! Join the Cure 4 The Kids Foundation Blood Drive and Registry Event - Nevada Business Magazine

Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit – Yahoo Finance

CEO Sandy Solmon to Present on Celavies Stem Cell Therapies at Upcoming Conferences in New York and Barcelona

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled "Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients," at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

The poster shows five-year follow-up data that expands on the exploratory clinical data in 7 PD patients with four-year follow-up published in Cell Transplantation in 2018. Oleg Kopyov, Executive Vice President and Chief Scientific Officer at Celavie, presented the poster on-site at the Miami Hyatt Regency.

In the results at one year after cell grafting, all but two of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. At five-year evaluation, Unified Parkinsons Disease Rating Scale III (UPDRS III) scores remained better than at baseline in 4/7 patients in the OFF condition and in 5/7 patients in the ON condition. None of the patients showed unwanted motor disturbances (dyskinesias), tumor formation, or any detectable immune responses to the grafted cells.

"We are excited that the five-year data for our exploratory clinical trial suggest that the neural progenitor cells are able to stop or slow down the motor deterioration in Parkinsons patients that one would expect to see in this timespan, showing continued improvement even compared to the fourth year," said Oleg Kopyov. "We anticipate filing an IND with the FDA for a Phase I U.S. trial in patients with moderate to advanced Parkinsons disease this year."

In addition, Sandy Solmon, Celavies CEO, will deliver presentations at two upcoming international industry conferences:

Ms. Solmon will discuss Celavies application of the companys human undifferentiated allogeneic pluripotent stem cells in Parkinsons disease, as well as pre-clinical data in cerebellar ataxia and upcoming milestones. To schedule a meeting with Celavie Biosciences at these conferences, please contact: Mary Beth Cicero at mbcicero@lavoiehealthscience.com.

About the World Stem Cell Summit

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About Celavie Biosciences

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at https://www.celavie.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005497/en/

Contacts

Hannah MongeonLaVoieHealthScience(617)655-6765hmongeon@lavoiehealthscience.com

Read the original post:
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Yahoo Finance

The Brave New World of Organoids – North Forty News

PHOTO COURTESY OF ROANE STATE COMMUNITY COLLEGE, TN: Typical nervous tissue that can now be grown as organoids in the lab.

Bio Bites

By R. Gary Raham

One of the big scientific news stories of 2019 involved the use of organoids to help fight disease, and to learn more about how embryos build entire human beings from one fertilized egg cell. The term organoids has a science fictiony sound to it. A title like Attack of the organoids wouldnt be out of place in an SF library. Actually, the ability to create specialized tissuelike bundles of brain neurons that hook together to transmit nerve impulsescan raise a few hairs on ones neck. But organoids do hold great promise for curing diseases, broadening our understanding of development, and personalizing medical treatments.

Stem cells allow scientists to build organoids. Stem cells are like major subcontractors produced by embryos to build the various organs and organ systems we depend on. These pluripotent cells (cells that can differentiate in many ways) can produce brain, kidney, lung, intestinal, stomach, and liver tissue. The tissue clumps produced tend to be smallroughly the size of a peapartly because they dont have access to the circulatory system the body uses to provide oxygen and nutrients and remove wastes. Scientists have to provide work-arounds to keep organoids alive and functioning.

One of the amazing things about organoids is that they self-organize into recognizable tissues without input from an entire body. Take brain cells for example. The neurons produced by stem cells link up and form networks that are capable of transmitting nerve impulses like an intact, complete brain. One leading researcher in this field of study is Alysson Muotri, a biologist at University of California San Diego School of Medicine. His website is http://www.medschool.ucsd.edu. He also has a fascinating series of YouTube videos called Building The Brain With Alysson Muotri. Muotri was senior author on a paper in 2019 in Cell Stem Cell. His lab was able to nurture the growth of brain organoids for many months. After four months electrical activity in the organoids began to increase exponentially. By twenty-five weeks, a computer program had a hard time distinguishing between brain wave patterns produced by organoids and pre-term babies.

Brain tissue organoids also hold promise for studying conditions like autism in human beingsa kind of neurological condition marked by differences in learning styles, repetitive motions, and sometimes difficulty with language and communication. The Harvard Stem Cell Institute is also studying how the Zika virus associates with microcephaly (small brain syndrome) during early embryo development.

Someday, scientists may be able to routinely take stem cells from individuals and test the efficacy of drugs on that persons liver cells, for example, to make sure those drugs wont produce harmful or fatal effects.

The brave new world of organoids is comingand not just in the next SF novel you read.

Go here to read the rest:
The Brave New World of Organoids - North Forty News

The Tiny Brain Cells That Connect Our Mental and Physical Health – WIRED

When enlarged under a high-resolution microscope, microglia resemble elegant tree branches with many slender limbs. As they pass by neurons, microglia extend and retract their tiny arm-like protrusions, tapping on each neuron as if to inquire, Are we good here? All okay? Or not okay?as a doctor might palpate a patients abdomen, or check reflexes by tapping on knees and elbows.

Back in 2004, Barres and Stevens were examining how synapses originally come to be pruned to form a healthy brain during early, normal development. Theyd recently discovered that immune molecules known as complement were sending out eat me signals from some brain synapses, and these synapsestagged with a kind of kiss of death signagewere destroyed. Think of the way you click and tag emails that you want deleted from your inbox. Your email servers software recognizes those tags, and when you click on the Trash icon, bing, theyre gone. Thats similar to what Stevens and Barres were seeing happen to brain synapses that were tagged by complement. They disappeared.

What they described happening in the brain, which they reported in the journal Cell in 2007, echoed a similar process that was well-understood to happen in the body. When a cell dies in a bodily organ, or if the bodys immune system senses a threatening pathogen, complement molecules tag those unwanted cells and invaders for removal. Then, a type of white blood cell known as macrophagesGreek for big eatersrecognizes the tag, engulfs the cell or pathogen, and destroys it. In the body, macrophages play a role in inflammation as well as in autoimmune diseases like rheumatoid arthritis and Guillain Barre. When activated, they can mistakenly go too far in their effort to engulf and destroy pathogens and spew forth a slew of inflammatory chemicals that begin to do harm to the bodys own tissue.

Stevens and Barres werent sure what was eating away at these tagged synapses, causing them to disappear in the brain, but Stevens had a hunch that it might have something to do with microglia.

We could see that when microglia sensed even the smallest damage or change to a neuron, they headed, spider-like, in that neurons direction, then they drew in their limbs and morphed into small, amoeba-like blobs, Stevens says. Soon after, those same synapses disappeared. Poof.

Could microglia be the culprit at the center of it all, the macrophage corollary in the brain, responding to eat me signals and pruning the brains circuitry during development? And what if this process was not only taking place in utero? Stevens wondered, when she first saw microglia behaving this way. What if it was also being mistakenly turned back on again later in life, during the teen years, or in adulthoodonly now its a bad thing and microglia are sometimes mistakenly engulfing and destroying healthy brain synapses too?

You can imagine how you could have too many synapses, or not enough synapse connectivity, Stevens says, her hands spreading wide with excitement. And you can imagine, given how our brain works, if that connectivity is even slightly off, that could potentially underlie a range of neuropsychiatric and cognitive disorders.

When she landed at Harvard, Stevens and her postdoc, Dori Schafer, tried to get a closer look at what microglia were up to in the brain. Schafer injected dye into the eyes of mice, which she then traced down from the neurons in the eye nerves and into the brain. This made the brains synapses glow bright fluorescent red. Microglia were stained fluorescent green. If they saw structuresthe synapsesglowing like red, fluorescent lit-up dots inside the bellies of the green microglia, they would know that microglia were eating synapses.

Six months into their efforts, Schafer came running into Stevenss office with photo images flapping in her hand. Theyre in there! she told Stevens. The synapses are inside the microglia! We can see it! It was such a high-five moment, Stevens recalls. Microglia were like tiny little Pac-Men in the brainand brain synapses were in the belly of the Pac-Men! We felt we were on to something really wonderful, really novel. This was deeply important in terms of looking ahead to microglias role in disease.

Read the original:
The Tiny Brain Cells That Connect Our Mental and Physical Health - WIRED

Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status – GlobeNewswire

MIAMI, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine Inc. (OTCPK:BPSR) (the Company) is pleased to provide shareholders and the investment community with an update on operations since its filing on November 1, 2018 of the Companys Annual Report on Form filing of Form 10-K for the year ended October 31, 2017, as well as the status of becoming fully compliant with SEC reporting obligations.

The Company is diligently working to complete its Quarterly Reports on Form 10-Q for the quarters ended January 31, 2018, April 30, 2018 and July 31, 2018 and its Annual Report on Form 10-K for the year ended October 31, 2018. In August 2019, the Company engaged Marcum LLP as its independent registered public accounting firm. The Company expects these reports to be completed and filed during the first calendar quarter of 2020. Following completion and filing of these reports, the Company expects to promptly proceed to preparation and filing of its Quarterly and Annual Reports for the fiscal year ended October 31, 2019, with the objective of becoming current in its SEC reporting requirements as soon as possible.

Since November 2018, the Company has remained focused on research and development activities and sale and distribution of anti-aging and cellular therapy derived products.

In February 2019, the Company recommenced its efforts to once again operate a perinatal tissue bank processing laboratory in Miami, Florida for the purpose of performing research and development and the manufacturing and processing of anti-aging and cellular therapy derived products. This new laboratory facility became operational in May 2019 and during the same period, the Company began producing products that are now being sold and distributed to its customers.

In addition, the Company has created what it believes is a world class research, medical and scientific advisory team. We believe that our team is one of the most qualified and industry reputable teams assembled to adequately address the current and expected future medical and regulatory challenges facing the Company and overall industry and to provide leadership in the ongoing development of superior quality products for use in the health care industry.

The Company has actively taken steps to assure that it meets compliance with current and anticipated United States Food and Drug Administration (FDA) regulations expected to be enforced beginning in November 2020 requiring that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (HCT/Ps) can only be sold pursuant to an approved biologics license application (BLA). On July 14, 2019, the Company received Institutional Review Board (IRB) approval to proceed with two pilot studies in connection with the Companys efforts to obtain Investigation New Drug (IND) approval from the FDA and commence clinical trials in connection with the use of the Companys products and related treatment protocols for specific indications. The Company is aggressively pursuing efforts to obtain the aforementioned IND approvals and commence and complete those clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available.

In an effort to increase sales and mitigate anticipated near future restrictions expected to be imposed by the FDA with respect to the use and distribution of Section 351 designated biologics, the Company is seeking to develop sales and distribution channels outside of the United States. In addition, the Company is focusing its efforts on developing other leading edge product offerings that would not fall within the FDA regulations for requiring a BLA license for U.S. manufacture and sale.

As a result of the Companys expected future increase in processing requirements and to enable it to perform certain advanced research and development activities, the Company is currently in negotiations to relocate its laboratory facility during the second calendar quarter of 2020 to a larger ISO 7 classified research and development and processing facility.

The Company has also been actively developing and expanding its sales, marketing and distribution network which it believes that based on the quality of the Companys existing products, the Companys commitment to regulatory compliance and superior research and development resources, the Company believes that it will be able to achieve desired growth during 2020.

The Company expects to provide periodic updates on operational and financial reporting developments as warranted.

For more information regarding the Company please visit our website at http://www.organicell.com.

About Organicell Regenerative Medicine, Inc.

Organicell is a leading, fully integrated Company focused in the field of regenerative medicine. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicines to revolutionize the field of regenerative medicine. We believe that our ground-breaking research in the field of nanotechnology, specifically exosome enrichments and other micro vesicles, is the next frontier of stem cell-based therapeutics. Organicell is committed to creating life changing and lifesaving therapies for patients.

Our mission is to transform regenerative medicine by continuing to combine exosome technology with other synergistic therapies and become the healthcare technology incubator for biologic medicine.

CAUTIONARY COMMENT REGARDING FORWARD-LOOKING STATEMENTS

The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Organicell Regenerative Medicine Inc., and its subsidiaries, plans and expectations, financial situation, the ability to retain key personnel, product acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, ability to expand sales and channels, and legislation or regulations affecting our operations and the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties. You are cautioned not to rely on these forward-looking statements. In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "intend", believes and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.

Management believes these forward-looking statements and the judgments upon which they are based to be reasonable, but they are not guarantees of future performance and involve numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, achievements or financial position to be materially different from any expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially from the forward-looking statements are set forth in our Form 10-K and other filings with the SEC. Other information can be obtained at http://www.organicell.com. The contents of the Companys website are not incorporated by reference in this Press Release.

Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press releases.

Organicell Regenerative Medicine Inc.4045 Sheridan Ave.Suite 239Miami Beach, FL 33140Website:http: http://www.organicell.comPhone: (888) 963-7881Email: info@organicell.com

Read more:
Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status - GlobeNewswire

At NSUH, a cell of the century in the Don Monti unit – Innovate Long Island

By GREGORY ZELLER //

That light at the end of the tunnel comes from the Northwell Health Cancer Institute, which provided hope and bona fide bone marrowy health improvements to a record number of patients last year.

As 2019 ticked down, staffers of the NHCIs Don Monti Adult Stem Cell Transplant Program gathered inside North Shore University Hospitalto recognize what Ruthee Lu-Bayer, chief of the Don Monti Bone Marrow Transplantation Unit, called a monumental milestone: the units 100th stem cell transplant of the year.

While any cancer clinic worth its salt is going to embrace hope, joy can be a rare commodity but the 100th stem cell transplant of 2019 triggered a full-on celebration at the Manhasset hospital, where stem cell transplants began in 1987 and are now performed in the 10-bed, inpatient Don Monti unit.

Complete with balloons, cake and a salute to No. 100 herself cancer-battling patient Teresa OHalloran the celebration assembled the units myriad doctors, nurses and other professionals, with Bayer applauding the combined efforts of every member of our staff who made this moment happen.

I always say that getting through their diagnosis is half the battle, the board-certified medical oncologist noted. When our patients arrive for transplant, I ask them to think of their transplant date as their second birthday, a time when they can begin to live their lives again.

Century mark: Don Monti Bone Marrow Transplantation Unit chief Ruthee Lu-Bayer and No. 100, Teresa OHalloran.

The gathering was also a celebration of the patients themselves, Bayer added, including OHalloran, whos fighting back against adult acute myeloid leukemia, a type of cancer in which the bone marrow produces abnormal white blood cells.

The 62-year-old East Islip resident, known affectionately as No. 100 around the unit, received the tough diagnosis last August and was admitted to NSUH in December for a bone marrow transplant. Following several days of preparatory chemotherapy, she received her infusion as the calendar flipped to 2020 and is now making an unusually rapid recovery, according to Northwell Health.

OHalloran, who joined the celebration from the safety of her isolated recovery room, credits her faith and positive outlook Ive always looked at the glass as half full, she noted and urged potential stem cell donors to check in with Be The Match, the national, nonprofit marrow-donor program.

I wish everyone could understand how important it is to be tested as a possible match, OHalloran added. Its a simple cheek swab and you could wind up saving someones life.

Visit link:
At NSUH, a cell of the century in the Don Monti unit - Innovate Long Island

Renew Stem Cell and Laser is Expanding Its Offering Outside of Scottsdale – Press Release – Digital Journal

Renew Stem Cell and Laser has a reputation for being a top provider of stem cell and laser treatments in Scottsdale. The high caliber clinic is excited to announce that they are currently expanding their service area to reach all of Arizona. Technicians are available to take appointments and give consultations.

Scottsdale, Arizona - Renew Stem Cell and Laser is excited to announce that starting now, clients all over Arizona will be able to enjoy their state of the art facility. The service menu is going to remain the same, for now. However, more clients will have access to the laser and stem cell therapies that Renew Stem Cell and Laser Scottsdale has to offer.

Renew Stem Cell and Laser is expanded their service areas to include all of Arizona, with the hopes of helping more clients. With multiple services available, clients are expected to flock to the facility. It is unclear yet as to if more services are going to be offered in the future. For now, this one of a kind facility is ready to lend a helping hand to customers outside of Scottsdale. Customers currently in Scottsdale do not have to worry about being pushed to the side. There are enough technicians and open appointments for treatments to accommodate an influx of clients.

This med spa in Scottsdale is excited to reach out to new clients who are in need of services. Consultations are currently being offered to new clients who arent sure which services are right for them. The facility promises that the quality of the treatments will not waiver at all, even though more clients are expected to sign up for services. The prices of services will also remain the same because Renew Stem Cell and Laser is a facility that is dedicated to their clients.

The public is urged to check out what this med spa has to offer in terms of services. Renew Stem Cell and Laser is excited to speak with clients about their facial and body treatments, which involve laser therapy. Many clients are ideal for stem cell therapy and dont even know it. Renew Stem Cell and Laser has decided to raise the bar and extend their service area to branch out to new clients. Numerous people in Arizona can now take advantage of everything on the service menu, without any restrictions.

In the past, Renew Stem Cell and Laser focused their services on the Scottsdale area. Now, the med spa is branching out to expand their service area to include all areas of Arizona. More exciting changes are expected for the future of this one of a kind company. The public is only expected to benefit as this facility makes changes towards bettering their services.

Media ContactCompany Name: Renew Stem Cell and LaserContact Person: Dr. Kerry PhelpsEmail: Send EmailPhone: (480) 869-4666Address:9700 N 91st St Suite B-112 City: ScottsdaleState: AZCountry: United StatesWebsite: renewstemcellandlaser.com/

Read the original:
Renew Stem Cell and Laser is Expanding Its Offering Outside of Scottsdale - Press Release - Digital Journal

Please Quit Telling Me It’s Not The Cancer – Curetoday.com

A cancer survivor talks about the side effects of cancer and chemo few people truly understand.

She has myelodysplastic syndrome, which is rare, and would love to communicate with others who have MDS.

However, I monitor any additional medical problems that I did not have before my cancer diagnosis. If it pops up afterward, there may be a reason. It is time to get online and to talk to my doctor about whether it is related to my cancer or treatment.

Recently, a friend came to my book club bruised from a fall after two stem cell implants. I asked her if anyone had told her chemo, every kind of chemo, can cause balance problems and she said no. No one told me either, and I found out from a trainer at the YMCA. I couldnt understand why when I leaned over to pick something up I would pitch forward. Physical therapy and personal training can assist with this, but we need to know first. This information should be given to every single cancer patient.

I had become increasingly irritated with people at my dentist's office telling me that having one tooth after another crack causing an extraction is due to my hard bite. A hygienist told me airily I had the hardest bite of any patient in the office!

Yes, I am nervous and grind my teeth, I do have bruxism, but to have 5 teeth removed in one year in 2019 is excessive! Finally, my oncologist shared with me that one of the chemos I was on weakens the bone structure. My dentist, who is wonderful, also researched and told me the same thing years after my diagnosis.

My audiologist originally thought my severe drop in hearing loss was due to Presbycusis or aging. I brought in an earlier audiogram to compare the precipitous drop. I then did some research proving the chemo I was on could because hearing loss. She was shocked and immediately went to work to help me.

I started suffering severe stomach pains and my oncologist referred me to a gastroenterologist. He did an endoscopy, found esophageal ulcers, and put me on medication. My PCP tried to tell me it was my age since he knew several patients with this problem. I did not believe him, because I never had problems before. Later the nurse practitioner for the specialist told me that cancer often does cause the ulcers. Again, my research also mentioned any compromised immune system problem such as cancer can lead to this problem that I used to start this conversation.

And, speaking of age, please do not tell me you know how I feel, because you are slowing down from age. Yes I get that and admit as an elderly person it takes me much longer to complete tasks. We all get more tired as we get older. However, that is not the same as the type of fatigue cancer survivors have, where we can be fine and suddenly drop and have to take to bed immediately.

Being forgetful is also part of old age and I know that, but that search for words known to every one of us with chemo brain is scary!

Many cancer survivors experience secondary cancers, total joint replacements from the bone density being reduced and countless other problems from the diseases or treatment. Sometimes it is not cancer-related. Joints do wear out. I have severe arthritis and had a rotator cuff surgery long before my cancer hit. The shoulder is worse now, but it is from gulp age! Our immune systems are affected by cancer too. We may get more frequent infections and need to watch carefully not to be around people who are sick.

Some people may ask if it really matters whether it is related to cancer or not. For us it does. My excellent audiologist keeps in touch with my oncologist and we monitor my remaining hearing. It was my oncologist who referred me to the specialist for the esophageal ulcers. The oncologist is truly unique because they work with so many specialists and family practitioners.

I ask myself why the doctors didnt tell me these side effects. It would take them all day to go over the possible side effects and scare the heck out of us. There are many side effects we will never have. However, it is up to us to know our bodies and to be vigilant in monitoring them. Cancer is an insidious and systematic disease and doesnt affect just one part of our body. However, by having a great relationship with our doctors, doing some basic research to start a dialogue with our doctors, and talking to other survivors, we can help ourselves.

It does not help to become paranoid and think about this all the time. Go read a book, watch a movie, play with your children and grandchildren and enjoy life. You are doing what you should and are better off for it!

See the article here:
Please Quit Telling Me It's Not The Cancer - Curetoday.com

Stem Cell Therapy Market Current Trends and Future Growth Dagoretti News – Dagoretti News

Stem Cell Therapy Market

MARKET INTRODUCTION

Stem cell therapy is a technique which uses stem cells for the treatment of various disorders. Stem cell therapy is capable of curing broad spectrum of disorders ranging from simple to life threatening. These stem cells are obtained from different sources, such as, adipose tissue, bone marrow, embryonic stem cell and cord blood among others. Stem cell therapy is enables to treat more than 70 disorders, including degenerative as well as neuromuscular disorders. The ability of a stem cell to renew itself helps in replacing the damaged areas in the human body.

MARKET DYNAMICSIncrease in the number of stem cell banking facilities and rising awareness on the benefits of stem cell for curing various disorders are expected to drive the market during the forecast period. Rise in number of regulations to promote stem cell therapy and increase in number of funds for research in developing countries are expected to offer growth opportunities to the market during the coming years.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPHE100000991/

The key players influencing the market are:

This report contains:

The stem cell therapy market is segmented based on type as, adult stem cell, embryonic stem cell induced pluripotent stem cell and others. The adult stem cells segment is further segmented as hematopoietic, umbilical cord, neuronal and mesenchymal stem cells. Based on treatment, the market is categorized as allogeneic and autologous. The market is categorized by application as, muscoskeletal, dermatology, cardiology, drug discovery & development and others.

Stem Cell Therapy Market Global Analysis to 2027 is an expert compiled study which provides a holistic view of the market covering current trends and future scope with respect to product/service, the report also covers competitive analysis to understand the presence of key vendors in the companies by analyzing their product/services, key financial facts, details SWOT analysis and key development in last three years. Further chapter such as industry landscape and competitive landscape provides the reader with recent company level insights covering mergers and acquisitions, joint ventures, collaborations, new product developments/strategies taking place across the ecosystem. The chapters also evaluate the key vendors by mapping all the relevant products and services to exhibit the ranking/ position of top 5 key vendors.

Stem Cell Therapy Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2018 2027, considering 2018 as the base year and 2018 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Report Spotlights

Purchase This Report @ https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Read the original:
Stem Cell Therapy Market Current Trends and Future Growth Dagoretti News - Dagoretti News

Memphis Meats raises $161m to build its cell-based meat platform: ‘We have a pretty clear path to bringing prices down to cost parity’ -…

The Series B round led by SoftBank Group, Norwest and Temasek and supported by Richard Branson, Bill Gates, Threshold Ventures, Cargill, Tyson Foods, Finistere, Future Ventures, Kimbal Musk, Fifty Years, CPT Capital, KBW Ventures and Vulcan Capital will enable Memphis Meats to reach a historic milestone of bringing its products to consumers, said the Berkeley-based firm.

It also opens doors in Asia, a strategically valuable market for cell-based meat, added the company, which has now raised more than $180m since its launch in 2015.

This signifies our shift from a company focused on research to a company focused on bringing products to consumers, David Kay, senior manager of communications and operations told FoodNavigator-USA.

Memphis Meats has not announced a date for product launch, but will likely begin with premium-priced products in restaurants, which are great places to engage in meaningful conversations with chefs and consumers and get useful feedback, said Steve Myrick,VP of Operations.

"We have been very careful to develop our production system so we can produce multiple types of meat from multiple species on the same equipment, so the pilot plant will be animal agnostic. It may produce chicken in one run and beef the next. As to what comes to market first, it's still an open question for us. We've prototyped beef, chicken and duck, and we've worked on other things we haven't announced."

Asked about the price tag for the first wave of products, he said: "We believe we have a pretty clear path to bringing prices down to essentially conventional cost parity, and that will definitely take some time and some very meaningful scale above and beyond what we will be able to do in the pilot plant.

"That said, we don't intend to wait until we are price parity before we bring anything to consumers, because we think it is very important to have product out in the world and start collecting feedback and start educating consumers about what this is and why they should care about it.We believe we have a pretty clear path to bringing prices down to essentially conventional cost parity [with meat from slaughtered animals].

"I think we will bring products to market initially at prices that are at a premium to many other meat producers but hopefully not a very extreme one."

As for consumer sentiment around cell-based meat, survey findings can vary widely depending on how questions are phrased, but he added: "Most of the research has shown two thirds of consumers with a willingness to try or buy and we think that's a really attractive baseline number [given that research also shows enthusiam tends to increase the more educated consumers are on this topic]."

As to what investors were looking for in this round, Myricksaid they were focused on Memphis Meats' ability to prove its production system was scalable and capable of producing a consistent product, coupled with proof that costs were coming down in a meaningful way.

"We really showed that we had a clear path as we increased scale to bringing costs down to something that consumers will be able to afford."

When it comes to intellectual property, he said, "We think that we've done innovative work across three separate areas of our production system: the cells themselves, the cell culture feed or media, and the production system - the hardware in which we're producing meat, and across all three of those there is potential to protect our work through both patents and trade secrets."

Most cell-based meat startups have developed prototypes at the lab-scale, but when it comes to commercial viability, they need cell lines that can replicate/proliferate extensively or even indefinitely (without having to keep going back to the original source) and differentiate into multiple cells types such as muscle, fat and connective tissue. They also need a production process that enables these cells to grow rapidly, and an affordable growth medium that doesnt utilize fetal bovine serum (FBS), a byproduct of the livestock industry.

Myrick would not provide details on how Memphis Meats has brought down the cost ofFBS-freegrowth media, but added: "We've explored a number of strategies for understanding what FBS does in our process and then replacing some of the key components of that with components that are detached from slaughter."

Asked about the production process, VP of product and regulation Eric Schulze said the initial cell proliferation phase and the next differentiation phase could be conducted in the same vessel or in separate vessels, although the company is not providing details of its chosen approach at this stage.

Similarly, the different cell types (fat, muscle, connective tissue etc) can be grown separately and then combined at the processing stage at the end, or they can be grown together, he said. "We've explored both [approaches]and we use both regularly in our processes."

Quizzed on whether the company was using edible or biodegradable scaffolds upon which to seed cells in order to create more structured or 'steak-like' products, he said: "The cells themselves produce a scaffold and we primarily rely on the cells to do that but we continue to explore all options on the table."

Asked whether the company was using induced pluripotent stem cells (which behave like embryonic stem cells in that they can replicate/proliferate extensively without having to keep going back to the original source and differentiate into multiple cells types), he said:"All of our cells have the ability to self-renew and they are derived from muscle, fat, and connective tissue."

Asked about the regulatory framework for cell-based meat in the US, Schulze said Memphis Meats was working closely with the FDA and USDA, which have set up three working groups looking at safety, inspections and labeling (read more about this HERE).

The US government was moving"efficiently behind the scenes and publicly as well," he said.

As for terminology, in an ideal scenario, stakeholders will settle upon a term that can be used by regulators and consumers, said Schulze, who favors the 'factual and descriptive,' but also 'neutral' term 'cell-based meat' over other options such as 'cultivated' meat.

*Prior to this, the largest deal closed for the industry was BlueNalu's $20m Series A in September 2019. Future Meat Technologies had a $14m Series A in October 2019 and Memphis Meats had a $17m Series A in August 2017.

An investment of this magnitude if it is followed by a commercially available product at a reasonable price point sends a signal to the market that cell-cultured meatis here today rather than some far-off future endeavor,predicted Bruce Friedrich at the Good Food Institute, which promotes cell-cultured and plant-based meat.

This investment round is a monumental milestone in the progress of the field. This is the biggest investment of its kind for cultivated meat and will help Memphis Meats move toward the scale they will need to get their products to market.

But he added: This is still an industry that has sprung up almost overnight and its important to keep a sense of perspective here. While the idea of cultivated meat has been percolating for close to a century, the very first prototype was only produced six years ago.

Continued resources will be needed for years to come While private investments in cultivated meat are essential, they need to be supported by public funding in order to sustain the industry moving forward.

I am proud to invest once again in Memphis Meats, the world's leading cell-based meat company. In the next few decades I believe that cell-based meat will become a major part of our global meat supply. I cannot wait for that day!

Richard Branson

To meet the growing global demand for protein, it will take all of us working together we need both animal and cell-based. Our continued investment in Memphis Meats underscores our inclusive approach to the future of meat. We need all options on the table to meet customer and consumer needs now and in the future.

Elizabeth Gutschenritter, managing director, Cargills alternative protein team

Continued here:
Memphis Meats raises $161m to build its cell-based meat platform: 'We have a pretty clear path to bringing prices down to cost parity' -...